Mga Batayang Estadistika
| LEI | 5299005I24806IOIYE03 |
| CIK | 906709 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nektar Therapeutics
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKT |
|
| August 8, 2025 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) Delaware 94-3134940 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification Number) 455 Mission Bay Boulevard South San Francis |
|
| August 8, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 NEKTAR THERAPEUTICS Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0. |
|
| August 8, 2025 |
Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended. Exhibit 4.8 NEKTAR THERAPEUTICS AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN 1. PURPOSE OF PLAN The purpose of this Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan (this “Plan”) of Nektar Therapeutics, a Delaware corporation (the “Corporation”), is to promote the success of the Corporation and to increase stockholder value by providing an additional means through t |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 000-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 7, 2025 |
Nektar Therapeutics Reports Second Quarter 2025 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Second Quarter 2025 Financial Results SAN FRANCISCO, August 7, 2025 - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025. Cash and investments in marketable securities on June 30, 2025 were $175.9 million as compared to $269.1 million on December 31, 2024. Nektar’s cash and marketable securities at |
|
| July 1, 2025 |
4,255,320 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-286222 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 1, 2025) 4,255,320 Shares of Common Stock We are offering 4,255,320 shares of our common stock, par value $0.0001 per share, or common stock, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Capital Market un |
|
| July 1, 2025 |
Nektar Therapeutics Announces Pricing of $100 Million Public Offering EX-99.1 Exhibit 99.1 Nektar Therapeutics Announces Pricing of $100 Million Public Offering SAN FRANCISCO, July 1, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering of $100 million of shares of its common stock |
|
| July 1, 2025 |
EX-1.1 Exhibit 1.1 4,255,320 Shares of Common Stock NEKTAR THERAPEUTICS UNDERWRITING AGREEMENT June 30, 2025 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Nektar Therapeutics, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 30, 2025 |
Subject to completion, dated June 30, 2025 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-286222 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2025 (June 24, 2025) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 24, 2025 |
Exhibit 99.2 1 Phase 2b REZOLVE - AD Topline Results from 16 - Week Induction Rezpegaldesleukin in Patients with Moderate - to - Severe Atopic Dermatitis June 24, 2025 Forward - Looking Statements 2 Safe Harbor Statement This presentation and any accompanying oral discussion contains forward - looking statements within the meaning of the Private Sec urities Litigation Reform Act of 1995, including |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 24, 2025 |
Exhibit 99.1 REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis Achieved statistical significance on primary endpoint at week 16 for mean percent change in EASI score from baseline for all rezpegaldesleukin arms versus placebo Achieved statistical significance for key secondary endpoints at week 16 of disea |
|
| June 6, 2025 |
Certificate of Amendment to the Amended Certificate of Incorporation of Nektar Therapeutics Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED CERTIFICATE OF INCORPORATION OF NEKTAR THERAPEUTICS Nektar Therapeutics (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST: This amendment to the Corporation’s Amended Certificate of Incorporation, as amended from time to ti |
|
| June 6, 2025 |
Certificate of Amendment to the Amended Certificate of Incorporation of Nektar Therapeutics Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED CERTIFICATE OF INCORPORATION OF NEKTAR THERAPEUTICS Nektar Therapeutics (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST: Effective upon the filing of this amendment to the Corporation’s Amended Certificate of Incorporatio |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 28, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 27, 2025 (May 23, 2025) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEK |
|
| May 8, 2025 |
Nektar Therapeutics Reports First Quarter 2025 Financial Results Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2025 Financial Results SAN FRANCISCO, May 8, 2025 - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024. Nektar’s cash and marketable securities are e |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 25, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 15, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2025 (April 3, 2025) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Nektar Therapeutics (Exact name of Registrant as Specified in Its Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| March 28, 2025 |
Form of indenture for senior debt securities and the related form of senior debt security. Exhibit 4.2 NEKTAR THERAPEUTICS Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Sect |
|
| March 28, 2025 |
VIA EDGAR March 28, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| March 28, 2025 |
Exhibit 4.3 NEKTAR THERAPEUTICS Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS3 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate |
|
| March 28, 2025 |
Equity Distribution Agreement, by and among the Registrant, Piper Sandler & Co. and BTIG, LLC. Exhibit 1.2 NEKTAR THERAPEUTICS EQUITY DISTRIBUTION AGREEMENT March 28, 2025 PIPER SANDLER & CO. 1251 6th Avenue, 6th Floor New York, NY 10020 BTIG, LLC 65 East 55th Street New York, NY 10022 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Nektar Therapeutics, a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to ti |
|
| March 28, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Nektar Therapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Primary Offering of Securities: Fees to Be Paid Equity Common Stock, par value $0. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 14, 2025 |
As filed with the Securities and Exchange Commission on March 14, 2025 As filed with the Securities and Exchange Commission on March 14, 2025 Registration No. |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| March 14, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Nektar Therapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| March 14, 2025 |
DRSLTR Goodwin Procter LLP 601 Marshall St. Redwood City, CA 94063 goodwinlaw.com +1 650 752 3100 March 14, 2025 CONFIDENTIAL SUBMISSION VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Nektar Therapeutics Draft Registration Statement on Form S-3 Ladies and Gentlemen: On behalf of Nektar Therapeutics (the “Company”), w |
|
| March 14, 2025 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on March 14, 2025. |
|
| March 14, 2025 |
Nektar Therapeutics Insider Trading Policy Exhibit 19.1 NEKTAR THERAPEUTICS SECURITY TRADING POLICY Nektar Therapeutics (“Nektar” or the “Company”) is committed to complying with all applicable laws and regulations. Nektar has adopted this Security Trading Policy (“Policy”) to prohibit Affiliates from trading in the securities of any company, including Nektar, while in possession of material, non-public information about such company, as w |
|
| March 14, 2025 |
Nektar Therapeutics Compensation Recovery Policy, dated June 8, 2023 Exhibit 97 Nektar Therapeutics COMPENSATION RECOVERY POLICY Adopted as of June 8, 2023 Nektar Therapeutics, a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. |
|
| March 14, 2025 |
Subsidiaries of Nektar Therapeutics. Exhibit 21.1 Subsidiaries of Nektar Therapeutics None. |
|
| March 14, 2025 |
Unaudited Pro Forma Condensed Consolidated Financial Statements for the year ended December 31, 2024 Exhibit 99 Unaudited Pro Forma Condensed Consolidated Financial Statements On December, 2, 2024, Nektar Therapeutics (Nektar, we) completed the sale (the Transaction) of our manufacturing facility located in Huntsville, Alabama (the Facility) and certain other manufacturing assets related thereto, including the assignment of our existing manufacturing and supply obligations, to Gannet BioChem, an affiliate of Ampersand Management LLC d/b/a Ampersand Capital Partners (Ampersand), via an Asset Purchase Agreement (the APA), for consideration of $64. |
|
| March 12, 2025 |
NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results SAN FRANCISCO, March 12, 2025 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023. Nektar’ |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 24, 2025 |
Exhibit 99.1 Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus - TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study - SAN FRANCISCO, CA and New York, NY, February 24, 2025 - Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes researc |
|
| February 14, 2025 |
Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G dated February 14, 2025 relating to the Common Stock, $0. |
|
| February 14, 2025 |
Exhibit B CONTROL PERSON IDENTIFICATION Samlyn Capital, LLC is the relevant entity for which Robert Pohly may be considered a control person. |
|
| February 14, 2025 |
EX-1 2 ex1.htm EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 2, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 14, 2024 |
NKTR / Nektar Therapeutics / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment SC 13G 1 eventidenektar-sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Nektar Therapeutics (Name of Issuer – as specified in its charter) Common Stock, $0.0001 par value (Title of Class of Securities) 640268108 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statemen |
|
| November 14, 2024 |
NKTR / Nektar Therapeutics / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-nktr093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* NEKTAR THERAPEUTICS (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 640268108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 7, 2024 |
Nektar Therapeutics Reports Third Quarter 2024 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2024 Financial Results SAN FRANCISCO, November 7, 2024 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar’s cash and m |
|
| November 4, 2024 |
Asset Purchase Agreement, dated as of November 1, 2024, between Nektar and Purchaser. Exhibit 1.1 Execution Version CONFIDENTIAL ASSET PURCHASE AGREEMENT by and between Nektar Therapeutics and [* * *] Dated as of November 1, 2024 Table of Contents Clause Page 1. Definitions and Terms 1 1.1 Definitions 1 1.2 Other Definitional Provisions 16 2. Purchase and Sale 17 2.1 Purchase and Sale of Assets 17 2.2 Consents 18 2.3 Excluded Assets 19 2.4 Assumption of Certain Obligations 21 2.5 E |
|
| November 4, 2024 |
MONDAY NOVEMBER 4, 2024 AT 5:30AM PT, 7:30 AM CT Exhibit 99.1 FINAL CONFIDENTIAL PRESS RELEASE FOR ISSUANCE MONDAY NOVEMBER 4, 2024 AT 5:30AM PT, 7:30 AM CT Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama Huntsville-based facility to be spun out as standalone Ampersand portfolio company. Nektar to receive $90 million in total consideration for the b |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 9, 2024 |
Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended.++ NEKTAR THERAPEUTICS AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN 1. PURPOSE OF PLAN The purpose of this Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan (this “Plan”) of Nektar Therapeutics, a Delaware corporation (the “Corporation”), is to promote the success of the Corporation and to increase stockholder value by providing an additional means through the grant of |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKT |
|
| August 8, 2024 |
Nektar Therapeutics Reports Second Quarter 2024 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Second Quarter 2024 Financial Results SAN FRANCISCO, August 8, 2024 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2024. Cash and investments in marketable securities at June 30, 2024 were $290.6 million as compared to $329.4 million at December 31, 2023. Nektar’s cash and marketable |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2024 (June 5, 2024) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 5, 2024 |
Up to 25,000,000 Shares of Common Stock Issuable Upon Exercise of the Pre-Funded Warrant Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279760 PROSPECTUS Up to 25,000,000 Shares of Common Stock Issuable Upon Exercise of the Pre-Funded Warrant This prospectus relates to the proposed resale or other disposition from time to time by the selling stockholder identified in this prospectus, or the Selling Stockholder, of up to an aggregate of 25,000,000 shares of our |
|
| June 3, 2024 |
VIA EDGAR June 3, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 28, 2024 |
As filed with the Securities and Exchange Commission on May 28, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 28, 2024 Registration No. |
|
| May 28, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0. |
|
| May 10, 2024 |
Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO PURCHASE AND SALE AGREEMENT This AMENDMENT NO. 1 TO PURCHASE AND SALE AGREEMENT (this “First Amendment”), dated as of March 4, 2024, is by and among Nektar Therapeutics, a Delaware corporatio |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEK |
|
| May 9, 2024 |
Nektar Therapeutics Reports First Quarter 2024 Financial Results Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2024 Financial Results SAN FRANCISCO, May 9, 2024 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securities at March 31, 2024 were $326.0 million as compared to $329.4 million at December 31, 2023. Nektar’s cash and marketable sec |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 15, 2024 |
NKTR / Nektar Therapeutics / TCG Crossover GP II, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NEKTAR THERAPEUTICS (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 640268108 (CUSIP Number) March 6, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the |
|
| March 15, 2024 |
EX-99.1 2 d800776dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that |
|
| March 5, 2024 |
Subsidiaries of Nektar Therapeutics. Exhibit 21.1 Subsidiaries of Nektar Therapeutics None. |
|
| March 5, 2024 |
w UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K Table of Contents w UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| March 5, 2024 |
Nektar Therapeutics Compensation Recovery Policy, dated June 8, 2023 Exhibit 97 Nektar Therapeutics COMPENSATION RECOVERY POLICY Adopted as of June 8, 2023 Nektar Therapeutics, a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 4, 2024 |
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results SAN FRANCISCO, March 4, 2024 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023. Cash and investments in marketable securities at December 31, 2023, were $329.4 million as compared to $505.0 million at December 31, |
|
| March 4, 2024 |
EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUB |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 4, 2024 |
EX-10.1 Exhibit 10.1 NEKTAR THERAPEUTICS SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of March 4, 2024 (the “Effective Date”), by and between NEKTAR THERAPEUTICS, a Delaware corporation (the “Company”), and TCG Crossover Fund II, L.P., a Delaware limited partnership (the “Purchaser”). WHEREAS, the Purchaser desires to purchase, and the Company has a |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 16, 2024 (February 12, 2024) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) |
|
| February 14, 2024 |
NKTR / Nektar Therapeutics / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm245429d14sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NEKTAR THERAPEUTICS (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 640268108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 14, 2024 |
EX-99.1 2 tm245429d14ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio |
|
| February 14, 2024 |
NKTR / Nektar Therapeutics / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
NKTR / Nektar Therapeutics / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243953d9sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* NEKTAR THERAPEUTICS (Name of Issuer) Common Stock, $0.0001 par value per share (the “Shares”) (Tit |
|
| February 13, 2024 |
NKTR / Nektar Therapeutics / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01524-nektartherapeutics.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Nektar Therapeutics Title of Class of Securities: Common Stock CUSIP Number: 640268108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to desi |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 27, 2023 (November 24, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) |
|
| November 8, 2023 |
Exhibit 10.1 Confidential Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and is the type that the registrant treats as private or confidential. Bristol-Myers Squibb Company Route 206 & Province Line Road Princeton, NJ 08543 September 6, 2023 Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, CA 94158 Attenti |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 |
|
| November 7, 2023 |
Nektar Therapeutics Reports Third Quarter 2023 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2023 Financial Results SAN FRANCISCO, November 7, 2023 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023. Cash and investments in marketable securities at September 30, 2023, were $372.7 million as compared to $505.0 million at December 31, 2022. Nektar’s cash and |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2023 (September 6, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) |
|
| August 17, 2023 |
NKTR / Nektar Therapeutics / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NEKTAR THERAPEUTICS (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 640268108 (CUSIP Number) August 07, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| August 14, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Nektar Therapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| August 14, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 9, 2023 |
Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended.++ NEKTAR THERAPEUTICS AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN 1.PURPOSE OF PLAN The purpose of this Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan (this “Plan”) of Nektar Therapeutics, a Delaware corporation (the “Corporation”), is to promote the success of the Corporation and to increase stockholder value by providing an additional means through the grant of a |
|
| August 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKT |
|
| August 9, 2023 |
EMPLOYMENT SEPARATION AND RELEASE AGREEMENT This Employment Separation and Release Agreement (“Agreement”) is entered into between Nektar Therapeutics, a Delaware corporation (the “Company”), and JILLIAN B. |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 8, 2023 |
Nektar Therapeutics Reports Second Quarter 2023 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Second Quarter 2023 Financial Results SAN FRANCISCO, August 8, 2023 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023. Cash and investments in marketable securities at June 30, 2023, were $409.4 million as compared to $505.0 million at December 31, 2022. Nektar’s cash and marketable |
|
| August 7, 2023 |
Exhibit 99.1 |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 7, 2023 |
Exhibit 99.2 Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company EASI-Related and PASI-Related Clinical Efficacy Endpoints in Atopic Dermatitis and Psoriasis Studies Were Incorrectly Calculated by Lilly and Were Reported Erroneously at EADV 2022 San Francisco, CA, A |
|
| July 10, 2023 |
NKTR / Nektar Therapeutics / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Nektar Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 640268108 (CUSIP Number) June 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| July 10, 2023 |
NKTR / Nektar Therapeutics / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Nektar Therapeutics Title of Class of Securities: Common Stock CUSIP Number: 640268108 Date of Event Which Requires Filing of this Statement: June 30, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 14)* Nektar Therapeutics (Name of Issuer) COM (Title of Class of Securities) 640268108 (CUSIP Number) June 30, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| July 3, 2023 |
NKTR / Nektar Therapeutics / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Nektar Therapeutics (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shares”) (Title of Class of Securities) 640268108 (CUSI |
|
| July 3, 2023 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Nektar Therapeutics, a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2023 (June 22, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2023 (June 8, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2023 (May 26, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 10, 2023 |
Consulting Agreement between Nektar Therapeutics and FLG Partners, LLC dated April, 2023++ CONFIDENTIAL CONSULTING AGREEMENT Exhibit 10.1 This Confidential Consulting Agreement (the “Agreement”) is executed as of the date shown on the signature page (the “Effective Date”), by and between FLG Partners, LLC, a California limited liability company (“FLG”), and Nektar Therapeutics, a Delaware company, with its principal place of business at 455 Mission Bay Boulevard South, Suite 100, San Fr |
|
| May 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEK |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2023 |
Nektar Therapeutics Reports First Quarter 2023 Financial Results Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2023 Financial Results SAN FRANCISCO, May 9, 2023 /PRNewswire/ – Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023. Cash and investments in marketable securities at March 31, 2023, were $456.8 million as compared to $505.0 million at December 31, 2022. Nektar’s cash and marketable se |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2023 (April 23, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Comm |
|
| April 27, 2023 |
Exhibit 99.1 Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development Company plans to move REZPEG forward into Phase 2 clinical study in atopic dermatitis SAN FRANCISCO, April 27, 2023 - Nektar Therapeutics (Nasdaq: NKTR) today announced that it will be regaining the |
|
| April 17, 2023 |
Exhibit 99.1 Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan - Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs - - Development of NKTR-255 in diffuse large B-cell lymphoma and bladder cancer to continue as strategic partnering options are pursued - - Cost restructuring plan reduces San Francisco-b |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 14, 2023 |
NKTR / Nektar Therapeutics / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 11, 2023 (April 6, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 13, 2023 |
Exhibit 99.1 Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank SAN FRANCISCO, March 11, 2023 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today issued a statement confirming that it does not have any accounts at Silicon Valley Bank, and it does not hold any cash deposits or securities at Silicon Valley Bank. At Decembe |
|
| February 28, 2023 |
Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results SAN FRANCISCO, Feb. 28, 2023 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2022. Cash and investments in marketable securities at December 31, 2022, were approximately $505.0 million as compared to $798.8 million at |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 28, 2023 |
Subsidiaries of Nektar Therapeutics. Exhibit 21.1 Subsidiaries of Nektar Therapeutics None. |
|
| February 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| February 23, 2023 |
Exhibit 99.2 Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus Improvement in SLEDAI-2K score observed as compared to placebo, although study did not meet primary endpoint Clinically meaningful improvements observed as compared to placebo across secondary endpoints including BICLA and LLDAS at the mid-dose level in the study Nekt |
|
| February 23, 2023 |
Exhibit 99.1 Phase 2 ISLAND Study of REZPEG in SLE Topline Data Results February 23, 2023 This presentation includes forward - looking statements regarding Nektar’s proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, unaudited year - end cash and investments and sufficiency of working capital and |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 9, 2023 |
SC 13G/A 1 nktra1320923.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13)* Nektar Therapeutics (Name of Issuer) COM (Title of Class of Securities) 640268108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box t |
|
| February 9, 2023 |
NKTR / Nektar Therapeutics / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01494-nektartherapeuticscl.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Nektar Therapeutics Class A Title of Class of Securities: Common Stock CUSIP Number: 640268108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate b |
|
| February 6, 2023 |
NKTR / Nektar Therapeutics / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Nektar Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 640268108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 2, 2023 |
NKTR / Nektar Therapeutics / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Nektar Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 640268108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 9, 2023 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 22, 2022 (December 16, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) |
|
| December 16, 2022 |
Amended and Restated Bylaws of Nektar Therapeutics. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF NEKTAR THERAPEUTICS (A DELAWARE CORPORATION) (amended and restated December 15, 2022) ARTICLE I OFFICES SECTION 1. REGISTERED OFFICE. The registered office of the corporation in the State of Delaware shall be as set forth in the Certificate of Incorporation of the corporation, as amended from time to time (the “Certificate of Incorporation”). SECTION 2. O |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2022 (December 15, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) |
|
| November 4, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 |
|
| November 3, 2022 |
Nektar Therapeutics Reports Third Quarter 2022 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2022 Financial Results SAN FRANCISCO, Nov. 3, 2022 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in marketable securities on September 30, 2022, were approximately $546.4 million as compared to $628.2 million at the end of the second quart |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 11, 2022 |
Exhibit 99.2 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THE INSIDE INFORMATION IS NOW CONSIDERED |
|
| October 11, 2022 |
Nektar Therapeutics (“Nektar”) Rule 2.8 Announcement Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR IMMEDIATE RELEASE 11 October 2022 Nektar Therap |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 7, 2022 |
PureTech Health plc Statement regarding recent press speculation Exhibit 99.1 October 6, 2022 PureTech Health plc Statement regarding recent press speculation PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (?PureTech? or the ?Company?) notes the recent press speculation and confirms that it has exchanged indicative, non-binding proposals with Nektar Therapeutics, Inc. (?Nektar?) regarding a possible combination (which may include, amongst other things, an offer |
|
| October 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 7, 2022 (October 6, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Co |
|
| August 5, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Nektar Therapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| August 5, 2022 |
Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan Exhibit 10.1 NEKTAR THERAPEUTICS AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN 1.PURPOSE OF PLAN The purpose of this Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan (this ?Plan?) of Nektar Therapeutics, a Delaware corporation (the ?Corporation?), is to promote the success of the Corporation and to increase stockholder value by providing an additional means through t |
|
| August 5, 2022 |
As filed with the Securities and Exchange Commission on August 5, 2022 As filed with the Securities and Exchange Commission on August 5, 2022 Registration No. |
|
| August 5, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKT |
|
| August 5, 2022 |
Exhibit 10.2 EMPLOYMENT TRANSITION, SEPARATION AND CONSULTATION AGREEMENT This Employment Transition, Separation and Consultation Agreement (this ?Agreement?) is entered into between Nektar Therapeutics, a Delaware corporation, defined to include its affiliated companies (including subsidiaries), employees, officers, directors, managers, agents, and shareholders, successors, assigns, and represent |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 4, 2022 |
Nektar Therapeutics Reports Second Quarter 2022 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Second Quarter 2022 Financial Results SAN FRANCISCO, August 4, 2022 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2022. Cash and investments in marketable securities at June 30, 2022, were approximately $628.2 million as compared to $798.8 million at December 31, 2021, which is expec |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2022 (June 29, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2022 (June 8, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2022 (May 19, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 6, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEK |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 5, 2022 |
Nektar Therapeutics Reports First Quarter 2022 Financial Results Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2022 Financial Results SAN FRANCISCO, May 5, 2022 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2022. Cash and investments in marketable securities at March 31, 2022 were approximately $704.4 million as compared to $798.8 million at December 31, 2021, which is expected |
|
| May 2, 2022 |
Material Impairments, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2022 (April 26, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 29, 2022 |
DEF 14A 1 d412608ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 25, 2022 |
Exhibit 99.1 Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook Company focusing on key pipeline programs NKTR-358, NKTR-255 and core research programs Cost restructuring plan results in cash runway into the first half of 2025 Analyst and investor conference call today at 5:00 PM ET (2:00 PM PT) SAN FRANCISCO, April 25, 2022 ? Nektar Therapeutics (Nasdaq: NKTR) today |
|
| April 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 14, 2022 |
Exhibit 99.1 Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) (PRINCETON, N.J., & SAN FRANCISCO, April 14, 2022) - Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegalde |
|
| March 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 14, 2022 |
Exhibit 99.1 Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma (PRINCETON, N.J., & SAN FRANCISCO, March 14, 2022) - Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) today announced an update following the first a |
|
| March 1, 2022 |
Subsidiaries of Nektar Therapeutics. Exhibit 21.1 Subsidiaries of Nektar Therapeutics Name Jurisdiction of Incorporation or Organization Inheris Biopharma, Inc. United States |
|
| March 1, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| March 1, 2022 |
Exhibit 10.40 [***] Certain confidential portions (indicated by brackets and asterisks) have been omitted from the exhibit in accordance with the rules of the Securities and Exchange Commission. AMENDMENT NO. 2 TO STRATEGIC COLLABORATION AGREEMENT This Amendment No. 2 (this ?Amendment No. 2?) to the Agreement (as defined below) is entered into as of January 12, 2022 (the ?Amendment No. 2 Effective |
|
| February 28, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 28, 2022 |
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results SAN FRANCISCO, Feb. 28, 2022 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Cash and investments in marketable securities at December 31, 2021 were approximately $0.8 billion as compared to $1.2 billion at Dece |
|
| February 11, 2022 |
NKTR / Nektar Therapeutics / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Nektar Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 640268108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12)* Nektar Therapeutics (Name of Issuer) COM (Title of Class of Securities) 640268108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 4, 2022 |
NKTR / Nektar Therapeutics / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* NEKTAR THERAPEUTICS (Name of Issuer) Common Stock (Title of Class of Securities) 640268108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 27, 2022 |
NKTR / Nektar Therapeutics / BlackRock Inc. Passive Investment us6402681083012722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 16) NEKTAR THERAPEUTICS - (Name of Issuer) Common Stock - (Title of Class of Securities) 640268108 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 11, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 10, 2022 |
NKTR / Nektar Therapeutics / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0014-nektartherapeuticscla.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Nektar Therapeutics Class A Title of Class of Securities: Common Stock CUSIP Number: 640268108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate b |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2021 (November 11, 2021) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) |
|
| November 9, 2021 |
Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, California 94158-2117 CORRESP 1 filename1.htm Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, California 94158-2117 November 9, 2021 VIA EDGAR Office of Life Sciences United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mary Mast, Senior Staff Accountant Re: Nektar Therapeutics Form 10-K for the Fiscal Year Ended Decembe |
|
| November 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2021 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 4, 2021 |
Nektar Therapeutics Reports Third Quarter 2021 Financial Results EX-99.1 2 ea149766ex99-1nektarthera.htm PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS" ISSUED BY NEKTAR THERAPEUTICS ON NOVEMBER 4, 2021 Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2021 Financial Results SAN FRANCISCO, November 4, 2021 - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, |
|
| August 18, 2021 |
As filed with the Securities and Exchange Commission on August 18, 2021 S-8 1 ea145918-s8nektarthera.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on August 18, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) Delaware 94-3134940 (State or Other Ju |
|
| August 6, 2021 |
Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan.++ Exhibit 10.1 NEKTAR THERAPEUTICS AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN 1.PURPOSE OF PLAN The purpose of this Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan (this ?Plan?) of Nektar Therapeutics, a Delaware corporation (the ?Corporation?), is to promote the success of the Corporation and to increase stockholder value by providing an additional means through t |
|
| August 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKT |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2021 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 5, 2021 |
Nektar Therapeutics Reports Second Quarter 2021 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Second Quarter 2021 Financial Results SAN FRANCISCO, August 5, 2021 - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2021. Cash and investments in marketable securities at June 30, 2021 were approximately $1.1 billion as compared to $1.2 billion at December 31, 2020. ?We continue to execute on our c |
|
| June 15, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2021 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 7, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEK |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2021 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 6, 2021 |
Nektar Therapeutics Reports First Quarter 2021 Financial Results Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2021 Financial Results SAN FRANCISCO, May 6, 2021 - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2021. Cash and investments in marketable securities at March 31, 2021 were approximately $1.1 billion as compared to $1.2 billion at December 31, 2020. ?We continue to build momentum with |
|
| April 30, 2021 |
DEF 14A 1 d174470ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 12, 2021 |
Form of indenture for senior debt securities and the related form of senior debt security. Exhibit 4.2 NEKTAR THERAPEUTICS Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certificate 6 Sect |
|
| March 12, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 12, 2021 Registration No. |
|
| March 12, 2021 |
Exhibit 4.3 NEKTAR THERAPEUTICS Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS3 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certificate |
|
| March 12, 2021 |
Sales Agreement dated March 12, 2021, by and among the Company and Cowen and Company, LLC. EX-1.2 2 d154330dex12.htm EX-1.2 Exhibit 1.2 NEKTAR THERAPEUTICS COMMON STOCK SALES AGREEMENT March 12, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Nektar Therapeutics (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time d |
|
| February 26, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| February 26, 2021 |
, 2021, by and between SFJ Pharmaceuticals XII, L.P. and Nektar Therapeutics.+ Exhibit 10.35 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. CO-DEVELOPMENT AGREEMENT This Co-Development Agreement (?Agreement?), made effective as of February , 2021 (the ?Effective Date?), is by and between Nektar Therapeutics, a Delaware corporation (?Nektar?), and |
|
| February 26, 2021 |
Exhibit 10.39 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. PURCHASE AND SALE AGREEMENT dated as of December 16, 2020 between NEKTAR THERAPEUTICS and HEALTHCARE ROYALTY PARTNERS IV, L.P., HCRP OVERFLOW FUND, L.P., HCR STAFFORD FUND, L.P., HCR POTOMAC FUND, L.P., and HC |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2021 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 25, 2021 |
Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results SAN FRANCISCO, Feb. 25, 2021/PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2020. Cash and investments in marketable securities at December 31, 2020 were approximately $1.2 billion as compared to $1.6 billion at Decem |
|
| February 17, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2021 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Nektar Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 640268108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 12, 2021 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Nektar Therapeutics Class A Title of Class of Securities: Common Stock CUSIP Number: 640268108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* NEKTAR THERAPEUTICS (Name of Issuer) Common Stock (Title of Class of Securities) 640268108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 11, 2021 |
Regulation FD Disclosure, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2021 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 5, 2021 |
Completion of Acquisition or Disposition of Assets - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2020 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 22, 2020 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2020 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 21, 2020 |
Amended and Restated Bylaws of Nektar Therapeutics. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF NEKTAR THERAPEUTICS (A DELAWARE CORPORATION) (amended and restated as of December 15, 2020) ARTICLE I OFFICES SECTION 1. REGISTERED OFFICE. The registered office of the corporation in the State of Delaware shall be as set forth in the Certificate of Incorporation of the corporation, as amended from time to time (the “Certificate of Incorporation”). SECTIO |
|
| December 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2020 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 |
|
| November 5, 2020 |
Nektar Therapeutics Reports Third Quarter 2020 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2020 Financial Results SAN FRANCISCO, November 5, 2020 - Nektar Therapeutics (NASDAQ: NKTR) today reported financial results for the third quarter ended September 30, 2020. Cash and investments in marketable securities at September 30, 2020 were approximately $1.2 billion as compared to $1.6 billion at December 31, 2019. "In Q3, we’ve continue |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2020 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 28, 2020 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 7, 2020 |
Employee Stock Purchase Plan, as amended and restated.++ nktr-2020x06x30xexx102 |
|
| August 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKT |
|
| August 7, 2020 |
Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan.++ nktr-2020x06x30xexx101 |
|
| August 7, 2020 |
S-8 As filed with the Securities and Exchange Commission on August 7, 2020 Registration No. |
|
| August 6, 2020 |
Nektar Therapeutics Reports Second Quarter 2020 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Second Quarter 2020 Financial Results SAN FRANCISCO, August 6, 2020 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020. Cash and investments in marketable securities at June 30, 2020 were approximately $1.2 billion as compared to $1.6 billion at December 31, 2019. This decrease inclu |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2020 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 23, 2020 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2020 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 8, 2020 |
Amended and Restated Compensation Plan for Non-Employee Directors Exhibit 10.1 AMENDED AND RESTATED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS This is the Compensation Plan (the “Plan”) for Non-Employee Directors (each a “Non-Employee Director”) of Nektar Therapeutics (the “Company”). This Plan was most recently amended and restated by the Board of Directors on March 20, 2019, and made effective as of January 1, 2019 as to cash compensation, and effective as o |
|
| May 8, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEK |
|
| May 7, 2020 |
Nektar Therapeutics Reports First Quarter 2020 Financial Results Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2020 Financial Results SAN FRANCISCO, May 7, 2020 — Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2020. Cash and investments in marketable securities at March 31, 2020 were approximately $1.5 billion as compared to $1.6 billion at December 31, 2019. “Amid the challenges of the evolvin |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2020 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 29, 2020 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 2, 2020 |
A Letter from our President & CEO, Howard Robin (updated April 1, 2020) Exhibit 99.1 A Letter from our President & CEO, Howard Robin (updated April 1, 2020) This is an unprecedented time. Nektar and our partners are navigating a complex situation of new and rapidly evolving information and guidelines. The safety and well-being of our fellow employees, and the patients and healthcare providers in our clinical trial programs, are of first and foremost importance to us. |
|
| April 2, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2020 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 28, 2020 |
nktr20191231ex1019 Exhibit 10.19 EMPLOYEE AGREEMENT In consideration of my employment or continued employment by Nektar Therapeutics, its subsidiaries or affiliates (collectively, the “Company”), I, John Northcott (name) residing at [***] (address) as of the date I was first employed by Company as follows: 1. Entire AAgreement:: This Agreement setss forth the completec and entire agreement between |
|
| February 28, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| February 28, 2020 |
Subsidiaries of Nektar Therapeutics. nktr20191231ex211 Exhibit 21.1 Subsidiaries of Nektar Therapeutics* Jurisdiction of Incorporation or Name Organization Nektar Therapeutics UK, Ltd. United Kingdom Nektar Therapeutics (India) Pvt. Ltd India Inheris Biopharma, Inc. United States * Includes subsidiaries that do not fall under the definition of “Significant Subsidiary” as defined under Rule 1-02(w) of Regulation S-X. |
|
| February 28, 2020 |
nktr20191213ex1035 Exhibit 10.35 [***] Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit in accordance with the rules of the Securities and Exchange Commission. AMENDMENT NO. 1 TO STRATEGIC COLLABORATION AGREEMENT This AMENDMENT NO. 1 (this “Amendment”) to the Agreement (as defined below) is entered into as of January 9, 2020 (the “Amendment Ef |
|
| February 28, 2020 |
nktr20191231ex1017 Exhibit 10.17 NEKTAR TRANSITION, SEPARATION, AND GENERAL RELEASE AGREEMENT RECITALS This Transition, Separation, and General Release Agreement ("Agreement") is entered into as of November 13, 2019 (the "Effective Date") and is made by and between Stephen Doberstein, Ph.D. ("Doberstein") and Nektar Therapeutics ("Company"). WHEREAS, Doberstein and Company entered into an Employee |
|
| February 28, 2020 |
nktr20191231ex44 Exhibit 4.4 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2019, Nektar Therapeutics (“Nektar,” the “Company,” “we,” “us,” and “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. DESCRIPTION OF CAPITAL STO |
|
| February 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2020 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 27, 2020 |
Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results SAN FRANCISCO, February 27, 2020 – Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2019. Cash and investments in marketable securities at December 31, 2019 were approximately $1.6 billion as compared to $1.9 billion at December 31, |
|
| February 12, 2020 |
NKTR / Nektar Therapeutics / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01216-nektartherapeutics.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Nektar Therapeutics Title of Class of Securities: Common Stock CUSIP Number: 640268108 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to desig |
